HomeTechnologyArtificial intelligenceXtalPi and CK Life Sciences to collaborate in AI-empowered tumour vaccine research...

XtalPi and CK Life Sciences to collaborate in AI-empowered tumour vaccine research and development, opening a new paradigm for scientific innovation

Currently there are only two therapeutic tumor vaccines: sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as preventive tumor vaccines against human papillomavirus infection and hepatitis B infection that have been approved by the US Food and Drug Administration (FDA) . Several other tumor vaccines have recently entered clinical development and have evidence of efficacy.

According to Mordor Intelligence, the global market size for cancer vaccines was $6.79 billion in 2021 and will increase at a compound annual growth rate of 11.53% from 2022 to 2026. The expected market size by 2026 will be approximately 12 billion dollars.

Currently, the design and preclinical development process for tumor vaccines is complex and lengthy, hampering the efficiency and success rate of tumor vaccine research and development.

This collaboration, which integrates XtalPi’s industry expertise in AI computation and robotic automation, aims to build an AI tumor vaccine R&D platform that applies advanced AI algorithms and high-precision molecular modeling to deliver a variety of predict and design tumor vaccines that can activate specific immune responses to kill tumors. The tumor vaccines will be screened and verified through automated experimentation, and by integrating algorithmic feedback to optimize activity and efficacy, the platform is expected to generate preclinical tumor vaccine candidates with robust immune activity.

dr. Shuhao Wenco-founder and chairman of XtalPi, notes, “As a company headquartered in Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, XtalPi is committed to realizing the synergies between Shenzhen and Hong-Kong by creating a new paradigm for innovation in the Greater Bay Area. Empowered by the latest technological advances in automation, artificial intelligence is accelerating more innovative and diverse areas in drug research and development. Together with CK Life Sciences, we are committed to overcoming conventional limitations and discovering diverse applications for advanced technologies. We believe the AI ​​platform for cancer vaccines, co-developed by CK Life Sciences and XtalPi, will inspire the global scientific community to advance vaccine research and development and accelerate key milestones in cancer vaccine development. We are confident that this collaboration will greatly facilitate the exchange of scientific research in the Greater Bay Area.”

Must Read
Worldwide Shortage of Healthcare Professionals Bolsters Sector Growth

dr. Melvin TohVice President and Chief Scientific Officer of CK Life Sciences, comments: “The R&D of tumor vaccines is one of the key development directions of CK Life Sciences. The partnership with XtalPi will apply XtalPi’s AI algorithm, molecular modeling and automated experimentation to accelerate R&D process, improve the success rate and increase the efficacy of tumor vaccines.”

About XtalPi

Founded in 2014, the founders of XtalPi saw a common hurdle in drug development related to solid polymorphism, which could be successfully addressed with predictions from quantum physics. Since then, XtalPi has focused on identifying and then addressing traditional bottlenecks in biopharmaceutical R&D through innovative technologies. Due to significant capital investments in automation and personnel, XtalPi now has four locations worldwide and approximately 1000 employees. XtalPi has engaged in research in collaboration with almost all top-20 pharmaceutical companies in the world. The ID4 platform combines physics-based simulations with experimental validation and refinement, automation for rapid synthesis, and machine learning to continuously improve prediction accuracy and process efficiency.

About CK Life Sciences

CK Life Sciences (stock code: 0775) is listed on the Stock Exchange of Hong-Kong. With a mission to improve the quality of life, CK Life Sciences engages in research and development, manufacturing, commercialization, marketing, sales and investment in products and assets that fall into three core categories: nutraceuticals, pharmaceuticals and agriculture-related. CK Life Sciences is part of the CK Hutchison Group.

Media contact:
Ruyu Wang
[email protected]
(617) 717-9867

SOURCE XtalPi Inc.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments